Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232180 · ClinicalTrials.gov registry record · Phase 3
A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines
A Phase 3 study of Heart Failure, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,743
- Enrollment target
- 20
- Study locations
NCT00232180 is a Phase 3 study of Heart Failure that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 2,743 participants, above the 2,042-participant average among 397 other Heart Failure trials with a reported enrollment target (34% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT00232180, a Phase 3 study of Heart Failure, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,743 participants
- Enrollment target
- 20
- Study locations
Study Summary
In an earlier study, eplerenone was shown to improve survival in patients who had heart failure immediately following a heart attack. However, it is not known how patients with established mild-to-moderate heart failure (NYHA Class II), who have the additional risk of sudden death, will respond if treated with eplerenone. In this trial, eplerenone plus standard heart failure medicines is being compared to placebo plus standard heart failure medicines in terms of an additional ability to prolong life and prevent re-hospitalizations for worsening heart failure in these patients. The Data Safety Monitoring Committee (DSMC) observed during its conduct of the protocol-specified second interim analysis on the 6th of May, 2010 that the efficacy of eplerenone had met the pre-specified stopping rules in the protocol. As a result of the discussion between the DSMC and the Executive Steering Committee (ESC), the ESC recommended that EMPHASIS-HF should be terminated, Based on the convincing efficacy and the consideration that it would be unethical not to offer this treatment to patients, the ESC recommended that all the patients in the trial should be transferred to open-label eplerenone. The Open Label Extension eplerenone arm will last for 12 months. Eplerenone is not currently approved for the indication studied in this patient population. On May 26, 2010, further enrollment into EMPHASIS-HF was stopped. The amendment is considered to be the most appropriate way to ensure that all the subjects who participated in the double-blind phase of the EMPHASIS-HF trial can be offered treatment with eplerenone
Conditions Studied
Interventions
- DRUG Eplerenone
Study Locations (20)
Florida
- Pfizer Investigational Site - Daytona Beach
- Pfizer Investigational Site - Gainesville
- Pfizer Investigational Site - Jupiter
- Pfizer Investigational Site - Melbourne
California
- Pfizer Investigational Site - Loma Linda
- Pfizer Investigational Site - Merced
- Pfizer Investigational Site - Stockton
Kentucky
- Pfizer Investigational Site - Louisville
- Pfizer Investigational Site - Louisville
- Pfizer Investigational Site - Louisville
Connecticut
- Pfizer Investigational Site - Bridgeport
- Pfizer Investigational Site - Hartford
Indiana
- Pfizer Investigational Site - Indianapolis
- Pfizer Investigational Site - Indianapolis
Arizona
- Pfizer Investigational Site - Phoenix
Colorado
- Pfizer Investigational Site - Colorado Springs
District of Columbia
- Pfizer Investigational Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,743 participants |
| Start Date | 2006-03 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00232180
The ClinicalTrials.gov registry entry for NCT00232180 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,743 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,042-participant average among 397 other Heart Failure trials with a reported enrollment target (34% higher). The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Eplerenone is the first listed.
NCT00232180 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00232180 about?
NCT00232180 is a clinical study titled "A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines". In an earlier study, eplerenone was shown to improve survival in patients who had heart failure immediately following a heart attack. However, it is not known how patients with established mild-to-moderate heart failure (NYHA Class II), who have the additional risk of sudden death, will respond if t...
What is the current status of trial NCT00232180?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,743 participants. The study started on 2006-03. Estimated completion is 2012-01.
What conditions does trial NCT00232180 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT00232180?
The interventions under investigation include: Eplerenone (DRUG).
Who is sponsoring clinical trial NCT00232180?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00232180 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.